NCT06487845View on ClinicalTrials.gov

A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 4, 2024

Primary Completion Date

September 19, 2024

Study Completion Date

September 19, 2024

Conditions
Chronic Kidney DiseaseNon-proliferative Diabetic RetinopathyHealthy Volunteers
Interventions
DRUG

BAY3283142

IR tablets, oral

DRUG

Placebo

Placebo matched to BAY3283142

Trial Locations (1)

510405

The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06487845 - A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter